Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose [corrected] [published erratum appears in J CLIN PHARM THER 2006 Apr;31(2):204].

OBJECTIVES: The present study was conducted to evaluate the safety, tolerability, and pharmacokinetics of TAS-108 after ascending single oral doses and to analyse preliminarily the effect of food on the pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects. METHODS: Twelve he...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 30; no. 5; pp. 459 - 471
Autores principales: Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Tsuda M, Shindo T, Nagayama S, Buzdar AU
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Oct2005
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106383356&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106383356
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Oct2005
      vid: 30
      iid: 5
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        106383356
        106383356
        2009080318
        10.1111/j.1365-2710.2005.00673.x
        NLM16164493
        106383356
      ppf: 459
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose [corrected] [published erratum appears in J CLIN PHARM THER 2006 Apr;31(2):204].
      aug:
        au:
          Yamaya H
          Yoshida K
          Kuritani J
          Yonezawa J
          Tsuda M
          Shindo T
          Nagayama S
          Buzdar AU
        affil: Pharmacokinetics Research Laboratory, Taiho Pharmaceutical Co., Ltd, 224-2 Hiraishi, Ebisuno, Kawauchi-cho, Tokushima 771-0194, Japan; hide-yamaya@taiho.co.jp
      sug:
        subj:
          Antimetabolites, Antineoplastic Therapeutic Use
          Breast Neoplasms Drug Therapy
          Estrogens Drug Effects
          Postmenopause
          Administration, Oral
          Adult
          Aged
          Antimetabolites, Antineoplastic Pharmacokinetics
          Biological Availability
          Chromatography, Liquid
          Data Analysis, Statistical
          Descriptive Statistics
          Female
          Japan
          Middle Age
          Mass Spectrometry
          Human
          Adult: 19-44 years
          Aged: 65+ years
          Middle Aged: 45-64 years
          Female
      ab: OBJECTIVES: The present study was conducted to evaluate the safety, tolerability, and pharmacokinetics of TAS-108 after ascending single oral doses and to analyse preliminarily the effect of food on the pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects. METHODS: Twelve healthy subjects participated in an open-label, ascending single-dose, alternating group, safety, tolerance, and pharmacokinetic study of TAS-108 administered orally to two groups of the subjects, one given alternating doses of 10, 40, 120 mg (group A) and the other of 20, 80, 160 mg (group B), in the fasting state. In addition, six subjects (group A) were administered an additional dose at 120 mg TAS-108 after food consumption. Plasma and urine samples for measurement of TAS-108 were analysed by validated analytical procedures using a liquid chromatographic method with tandem mass spectrometric detection (LC/MS/MS). RESULTS: There was no dose-dependent increase in any adverse events (AEs), and there were no serious AEs or deaths. TAS-108 was readily absorbed following oral administration of the 80-, 120- and 160-mg doses. Plasma TAS-108 levels steadily declined, generally in a mono-exponential manner, with overall mean t(1/2) values ranging from 3.04 to 4.43 h in the fasting groups. Administration of TAS-108 after a high-fat meal markedly increased the bioavailability of the drug. The mean C(max) and AUC(0--t) values increased after a high-fat breakfast by 182 and 191% compared with the fasting value respectively. CONCLUSIONS: In this escalating dose study of TAS-108, the drug was well tolerated by the participants. The maximum and systemic exposure to TAS-108 tended to increase with increasing dose and its bioavailability markedly increased after high-fat food intake.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N